go-v.orgdoi

Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity

Partow Kebriaei · Frontiers in Bioscience-Scholar · 2011

  • DOI 10.2741/282
  • Publisher IMR Press
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Frontiers in Bioscience-Scholar · IMR Press · article · 2011

Abstract

Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells.

Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.

Open the resolved locator · 10.2741/282

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:33 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.imrpress.com/journal/FBS/4/2/10.2741/s282
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.